The pivotal role of EMT-related noncoding RNAs regulatory axes in hepatocellular carcinoma

Frontiers in Pharmacology

Pharmacology

Andrei Sorop¹  Alina-Veronica Ghionescu¹  Simona Olimpia Dima² 

[1] Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania;Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania;Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania;Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;

关键词: hepatocellular carcinoma;    noncoding RNA;    epithelial-mesenchymal transition;    chemoresistance;    exosomes;   

DOI  :  10.3389/fphar.2023.1270425

 received in 2023-07-31, accepted in 2023-08-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma (HCC) remains a major health problem worldwide, being the leading cause of cancer-related deaths, with limited treatment options, especially in its advanced stages. Tumor resistance is closely associated with the activation of the EMT phenomenon and its reversal, being modulated by different molecules, including noncoding RNAs (ncRNAs). Noncoding RNAs have the potential to function as both tumor suppressors and oncogenic molecules, controlling the malignant potential of HCC cells. Basically, these molecules circulate in the tumor microenvironment, encapsulated in exosomes. Their impact on cell biology is more significant than originally expected, which makes related research rather complex. The temporal and spatial expression patterns, precise roles and mechanisms of specific ncRNAs encapsulated in exosomes remain primarily unknown in different stages of the disease. This review aims to highlight the recent advances in ncRNAs related to EMT and classifies the described mechanism as direct and indirect, for a better summarization. Moreover, we provide an overview of current research on the role of ncRNAs in several drug resistance-related pathways, including the emergence of resistance to sorafenib, doxorubicin, cisplatin and paclitaxel therapy. Nevertheless, we comprehensively discuss the underlying regulatory mechanisms of exosomal ncRNAs in EMT-HCC via intercellular communication pathways.

【 授权许可】

Unknown   
Copyright © 2023 Ghionescu, Sorop and Dima.